Epidemiology Insights and Forecast
Disease Burden insights, powered with real-world data
Thelansis provides robust epidemiology insights built on validated methodologies, real-world registries, healthcare utilization data, clinical literature, and expert review. Our Epidemiology Insights deliver a comprehensive understanding of disease burden, by prevalence, incidence, diagnosed cases, comorbidities, clinical manifestations and severity stratification across geographies. This help quantify the true patient population, disease progression, and forecast trends across major global markets.
What We Provide:
- 8 MM/20+ Country Epidemiology Forecasts
- Prevalence, Incidence, Mortality & Survival Estimates
- Population Segmentation by Stage, Biomarker, Severity & Line of Therapy
- Prognostic Subgroup Analysis for targeted therapies
- Population Flow Models (undiagnosed → diagnosed → treated → eligible)
- Methodology Based on Published Literature, Registries & Expert Validation
How It Helps You:
Accurate epidemiology is essential for:
- Opportunity assessment and market sizing
- Clinical development planning
- Reimbursement dossiers
- Commercial strategy and resource allocation
- Health technology assessments (HTA)
What Strategic Answers Clients Will Receive:
- How large is the patient population today (incidence, prevalence, segments)?
- How will the epidemiology evolve over time, and what factors will drive those changes?
- What are the key patient subgroups by stage, biomarker, severity, and treatment status?
- How does patient progression flow across the disease continuum?
- What is the realistic addressable patient pool for current and future therapies?
- How do epidemiology trends differ across the US, EU5, Japan, China, and other 20+ emerging markets?
Reports:
Market Outlook and Forecast
Thelansis’s “Lamb-Shaffer Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lamb-Shaffer Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Severe Eosinophilic Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Eosinophilic Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Vanishing White Matter Disease (VWMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vanishing White Matter Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Arginine Vasopressin Deficiency (AVP-D) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Arginine Vasopressin Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Locally Advanced or Metastatic HER2-Negative Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic HER2-Negative Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Access and Reimbursement Insights
Thelansis’s “Dyslipidemia Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

